These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 8968092)
21. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196 [TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Latham JP; Searle PF; Mautner V; James ND Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585 [TBL] [Abstract][Full Text] [Related]
23. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647 [TBL] [Abstract][Full Text] [Related]
24. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725 [TBL] [Abstract][Full Text] [Related]
25. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Pannek J; Rittenhouse HG; Evans CL; Finlay JA; Bruzek DJ; Cox JL; Chan DW; Subong EN; Partin AW Urology; 1997 Nov; 50(5):715-21. PubMed ID: 9372881 [TBL] [Abstract][Full Text] [Related]
27. Free and total human glandular kallikrein 2 in patients with prostate cancer. Väisänen V; Pettersson K; Alanen K; Viitanen T; Nurmi M Urology; 2006 Jul; 68(1):219-25. PubMed ID: 16844459 [TBL] [Abstract][Full Text] [Related]
28. Ala217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Mikolajczyk SD; Millar LS; Marker KM; Grauer LS; Goel A; Cass MM; Kumar A; Saedi MS Eur J Biochem; 1997 Jun; 246(2):440-6. PubMed ID: 9208936 [TBL] [Abstract][Full Text] [Related]
29. Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mize GJ; Wang W; Takayama TK Mol Cancer Res; 2008 Jun; 6(6):1043-51. PubMed ID: 18567807 [TBL] [Abstract][Full Text] [Related]
30. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382 [TBL] [Abstract][Full Text] [Related]
31. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. Slawin KM; Shariat SF; Nguyen C; Leventis AK; Song W; Kattan MW; Young CY; Tindall DJ; Wheeler TM Cancer Res; 2000 Dec; 60(24):7142-8. PubMed ID: 11156423 [TBL] [Abstract][Full Text] [Related]
32. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. Denmeade SR; Lövgren J; Khan SR; Lilja H; Isaacs JT Prostate; 2001 Jul; 48(2):122-6. PubMed ID: 11433422 [TBL] [Abstract][Full Text] [Related]
33. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Yousef GM; Scorilas A; Chang A; Rendl L; Diamandis M; Jung K; Diamandis EP Prostate; 2002 May; 51(2):126-32. PubMed ID: 11948967 [TBL] [Abstract][Full Text] [Related]
34. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565 [TBL] [Abstract][Full Text] [Related]
35. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Denmeade SR; Sokoll LJ; Chan DW; Khan SR; Isaacs JT Prostate; 2001 Jun; 48(1):1-6. PubMed ID: 11391681 [TBL] [Abstract][Full Text] [Related]
36. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616 [TBL] [Abstract][Full Text] [Related]
37. Human tissue kallikrein 9: production of recombinant proteins and specific antibodies. Memari N; Grass L; Nakamura T; Karakucuk I; Diamandis EP Biol Chem; 2006 Jun; 387(6):733-40. PubMed ID: 16800734 [TBL] [Abstract][Full Text] [Related]
38. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Charlesworth MC; Young CY; Klee GG; Saedi MS; Mikolajczyk SD; Finlay JA; Tindall DJ Urology; 1997 Mar; 49(3):487-93. PubMed ID: 9123724 [TBL] [Abstract][Full Text] [Related]
39. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Scorilas A; Plebani M; Mazza S; Basso D; Soosaipillai AR; Katsaros N; Pagano F; Diamandis EP Prostate; 2003 Feb; 54(3):220-9. PubMed ID: 12518327 [TBL] [Abstract][Full Text] [Related]